Evidence map›Paper›PMID 42624909›Full record

ArticleActa pharmacologica Sinica2026

Targeting CYBA inhibits hepatic metastasis of pancreatic cancer through AKT/MLC2 pathway.

Hao-Jie Du, Wen Fang, Qin-Chang Zhang, Na-Na Chen, Feng-Lin Zhang, Jian-Gang Zhao, Ji-Hong Lv, Kong Mingyui Anthony, Hao Chen, Jian-Jun Zou and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hao-Jie Du *State Key Laboratory of Pharmaceutical Biotechnology and Nanjing Drum Tower Hospital, School of Life Sciences, Chemistry and Biomedicine Innovation Center, Nanjing University, Nanjing, 210023, China.
Wen Fang *State Key Laboratory of Pharmaceutical Biotechnology and Nanjing Drum Tower Hospital, School of Life Sciences, Chemistry and Biomedicine Innovation Center, Nanjing University, Nanjing, 210023, China.
Qin-Chang Zhang *Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of Tumor, The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Na-Na Chen *State Key Laboratory of Pharmaceutical Biotechnology and Nanjing Drum Tower Hospital, School of Life Sciences, Chemistry and Biomedicine Innovation Center, Nanjing University, Nanjing, 210023, China.
Feng-Lin ZhangOncology Department of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Jian-Gang ZhaoOncology Department of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Ji-Hong LvState Key Laboratory of Pharmaceutical Biotechnology and Nanjing Drum Tower Hospital, School of Life Sciences, Chemistry and Biomedicine Innovation Center, Nanjing University, Nanjing, 210023, China.
Kong Mingyui AnthonyState Key Laboratory of Pharmaceutical Biotechnology and Nanjing Drum Tower Hospital, School of Life Sciences, Chemistry and Biomedicine Innovation Center, Nanjing University, Nanjing, 210023, China.
Hao ChenDepartment of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. chengkll@sina.com.
Jian-Jun ZouDepartment of Clinical Pharmacology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China. zoujianjun100@126.com.
Yang SunState Key Laboratory of Pharmaceutical Biotechnology and Nanjing Drum Tower Hospital, School of Life Sciences, Chemistry and Biomedicine Innovation Center, Nanjing University, Nanjing, 210023, China. yangsun@nju.edu.cn.
Hai-Bo ChengJiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of Tumor, The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, 210023, China. haibocheng@njucm.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer is known as the "king of cancers", mainly due to its aggressive metastatic potential and significant heterogeneity. The liver represents the most frequent site of distant metastasis in pancreatic ductal adenocarcinoma (PDAC). Currently, effective treatment options remain critically limited for patients diagnosed with PDAC-derived hepatic metastases. In our research, we integrated single-cell transcriptomic data from multiple samples to delve into the heterogeneity of epithelial cells. We identified a subtype of malignant metastatic epithelial cells and identified CYBA, which encodes the p22

Indexed as

CYBAMLC2motor protein polymerizationp22phoxpancreatic cancer hepatic metastasisPI3K-AKT signaling pathway

Identifiers

PMID42624909

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.